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Abstract 
 
Background: The Society of Neurointerventional Surgery (SNIS) revised its’ operational 
definition of Emergent Large Vessel Occlusion (ELVO) recently to include proximal M2 
segment MCA occlusions. We sought to assess the benefit of EVT over best medical care for M2 
segment MCA occlusion. 
Methods: Patient level data from trials in the HERMES Collaboration were included. The 
HERMES core lab identified patients with M2 segment MCA occlusions and further classified as 
proximal vs. distal, anterior vs. posterior division and dominant vs. co-dominant vs. non-
dominant. Primary outcome was mRS 0-2 at 90 days. Secondary outcomes were mTICI rates at 
end of procedure, 90-day mRS shift, 90-day mRS 0-1, 24 hr NIHSS 0-2, symptomatic ICH and 
death.   
Results: 130 patients with M2 MCA (proximal location n=116 vs. distal n=14, anterior division 
n=72 vs. posterior n=58, dominant n=73 vs. co-dominant n=50 vs. non-dominant n=7) were 
included. Successful reperfusion (mTICI 2b or 3) among those undergoing EVT was seen in 
59.2% patients. Treatment effect favored EVT (adjusted OR 2.39, 95% CI 1.08-5.28, p=0.03) for 
90-day mRS 0-2 (58.2% EVT vs. 39.7% control). Direction of benefit favored EVT for other 
outcomes. Treatment effect favoring EVT was maximal in patients with proximal M2 segment 
MCA occlusions (n=116, adjusted OR 2.68, 95% CI 1.13-6.37) and in dominant M2 segment 
MCA occlusions (n=73, adjusted OR 4.08, 95% CI 1.08-15.48). No sICH (0%) was observed in 
patients treated with EVT compared to 5 (7.8%) in the control arm. 
Conclusion: Patients with proximal M2 segment MCA occlusions eligible for EVT trial 
protocols benefited from EVT. 
 
  
Introduction 
 
Endovascular thrombectomy (EVT) works by recanalizing intracranial arteries in a timely and 
safe manner, saving ischemic brain from irreversible injury.1 The presence of salvageable brain 
tissue along with a target arterial occlusion that could be recanalized in a time bound manner and 
the safety of the procedure during such an attempt were the primary reasons why recent clinical 
trials showed efficacy of EVT over standard care.2 3 In an effort to establish a beachhead of 
evidence for EVT during a time when prior trials had shown lack of efficacy of EVT, trials 
published in 2015-17 focused on the more accessible, larger vessel anterior circulation (internal 
carotid artery and M1 segment middle cerebral artery) occlusions.4 These occlusion sites also 
lend themselves easily to imaging selection strategies used in these trials (e.g. NCCT ASPECTS, 
CTP ischemic core volume or CTA collateral assessments).5 6 Patients with M2 segment MCA 
occlusions were either deliberately excluded (e.g. in the ESCAPE, SWIFT PRIME, 
REVASCAT, THRACE and PISTE trials) or were under-sampled (e.g. in the MR CLEAN and 
the EXTEND IA trials).2 Questions about efficacy of EVT in patients with M2 segment MCA 
occlusions remain.7-9 
 
Many proximal M2 MCA segment occlusions are as easily accessible for EVT as M1 segment 
MCA occlusions.8 Some M2 segment MCA arteries are the dominant artery supplying blood to a 
large portion of the MCA territory.10 A recent meta-analysis of data from 12 non-randomized 
studies suggested that EVT for patients with M2 segment MCA occlusions that can be safely 
accessed is associated with high recanalization rates and good clinical outcomes.7 Using patient 
level data from the HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular 
Stroke Trials) Collaboration therefore, we sought to test the hypothesis that EVT would result in 
better clinical outcomes among patients with M2 segment MCA occlusions when compared to 
standard care. In addition, we asked whether certain anatomical characteristics of M2 segment 
MCA occlusions such as location, size, anatomy and number of vessels occluded lend 
themselves better to EVT than others. 
 
Methods 
The HERMES collaboration includes patient level data from the MR CLEAN, ESCAPE, 
REVASCAT, SWIFT PRIME, THRACE, EXTEND IA and PISTE randomized controlled trials. 
Differences in patient population, sampling frame and operational definitions of intervention 
(EVT) and control have been published previously.6 All baseline imaging was read by the 
HERMES central core lab blinded to clinical information. The core lab identified thrombus 
location at baseline on CT Angiography (preferably) or MR Angiography. Thrombus location 
was classified as either internal carotid artery (ICA), proximal and distal M1 segment middle 
cerebral artery (MCA) or M2 segment MCA. An occlusion was considered to be in the distal M1 
segment MCA and not in a M2 segment MCA if the only patent MCA arterial branch proximal 
to the occlusion was the anterior temporal artery.10 11 The M2 segment MCA with thrombus was 
sub-classified based on a) location (assessed on coronal images; proximal to the mid-sylvian 
point vs. distal) b) vascular territory supplied [anterior division (supplying the anterior MCA 
region) vs. posterior (supplying the posterior MCA region)] c) size [dominant division 
(supplying >50% of the MCA territory) vs. co-dominant (50% of the MCA territory)  vs. non-
dominant (<50% of the MCA territory)] and d) number (one branch involved vs. more than one). 
Subject count included in analyses by trial were MR CLEAN (n=46), ESCAPE (n=18), 
EXTEND-IA (n= 9), SWIFT PRIME (n=24), REVASCAT (n=21), PISTE (n=4) and THRACE 
(n=8).  
 
Since M2 segment MCA occlusions only cause ischemia to a part of the MCA territory, it is 
reasonable to assume that patients with such occlusions are less likely to have large infarcts that 
are more commonly associated with a bed ridden state or death even when not treated with EVT. 
Maximal benefit with EVT vs. standard care is therefore likely to be seen on the lower end of the 
modified Rankin Scale with minimal gains across higher levels of this scale.12 We therefore 
chose functional independence (mRS 0-2) as the primary outcome for this analysis. Secondary 
outcomes included excellent functional outcome (mRS 0–1) at 90 days, shift in mRS distribution 
at 90 days and dramatic neurological improvement (defined as NIHSS 0-2 24 hours after stroke 
onset). Technical efficacy was assessed by revascularization at end of endovascular procedure 
defined using modified Thrombolysis in Cerebral Infarction (mTICI) scale score of 2b or 3, 
corresponding to reperfusion of at least 50% of the affected vascular territory. Safety outcomes 
included symptomatic intracranial hemorrhage (sICH; defined by each trial) and death within 90 
days. 
 
Statistical Analysis 
All analyses were by intention to treat. Mixed-effects modeling was used for all analyses, with 
fixed effects for parameters of interest and “trial” and the interaction term “trial*treatment” as 
random effects variables in all models. All adjusted regression models (binary logistic and 
ordinal) included fixed effects (age, sex, NIHSS score at admission, intravenous alteplase use 
and time from onset to randomization).  Heterogeneity of treatment effect by pre-specified 
clinical sub-groups [age <=70 vs. > 70 years, sex, NIHSS score at admission (<=10, 11-15, >15), 
baseline NCCT ASPECTS (<=8 vs. 9-10), intravenous alteplase use and time from stroke onset 
to randomization <=300 mins vs. > 300 mins) was assessed. Treatment effect in M2 segment 
MCA sub-types with sufficient sample size were also reported. All statistical analyses were 
performed using SAS v.9.2 (SAS Institute, Cary, North Carolina). 
 
Role of the funding source 
The funders of the study had no role in study design, data analysis, data interpretation, or writing 
of the report.  
 
Results 
Baseline characteristics and workflow processes of patients with M2 segment MCA occlusions 
in the EVT and control groups are described in Table 1. After excluding one patient with missing 
90-day outcome, 130 patients with M2 segment MCA occlusions (proximal location n=116 vs. 
distal n=14, anterior division n=72 vs. posterior division n=58, dominant n=73 vs. co-dominant 
n=50 vs. non-dominant n=7, single vessel n=123 vs. multi-vessel n=7) were included for further 
analysis. Sixty-seven patients were randomised to the EVT arm and 63 patients to the control 
arm. Successful reperfusion (mTICI 2b or 3) was observed in 59.2% patients. Infarct core 
volumes at baseline were assessed on 64 patients (51 subjects using baseline CTP vs. 13 baseline 
MRI). Median core volume was 12.6 ml (IQR 2.9, 28.6) by central assessment.   
 
 
Figure 1 shows the distribution of mRS in the intervention arm vs. control in all patients included 
in this analysis. Treatment effect favored EVT over control (adjusted OR 2.39, CI95 1.08-5.28, 
p=0.03) for mRS 0-2 at 90 days. The corresponding unadjusted odds ratio was 2.13 (CI95 1.05 – 
4.35; p=0.04; 58.2% with EVT vs. 39.7% control respectively) while the number needed to treat 
for 1 patient to have functional independence (mRS 0-2) was 5.4.  The direction of benefit 
favored EVT over control for other outcomes, but results were not conventionally statistically 
significant (Table 2). No sICH or major procedural complications (0%) were noted among 
patients treated with EVT compared to 5 (7.8%) in the control arm. Death at 90 days occurred in 
11.9% patients in the EVT group vs. 9.5% in the control group (p=0.66). No statistically 
significant heterogeneity in treatment effect was noted by age, sex, NIHSS score at admission, 
baseline NCCT ASPECTS, intravenous alteplase use and time from stroke onset to 
randomization (all p>0.05). 
 
Treatment effect favoring EVT was maximal in patients with proximal M2 segment MCA 
occlusions (n=116, adjusted OR 2.68, 95% CI 1.13-6.37, p=0.02 for mRS 0-2 at 90 days, 57.1% 
EVT vs. 37.7% control, respectively), when the involved M2 segment MCA was dominant 
(n=73, adjusted OR 4.08, 95% CI 1.08-15.48, p=0.04 for mRS 0-2 at 90 days, 61.5% EVT vs. 
44.1% control, respectively) and when a single M2 segment MCA was involved (n=123, 
adjusted OR 2.73, 95% CI 1.19-6.27, p=0.02 for mRS 0-2 at 90 days, 58.5% EVT vs. 37.9% 
control, respectively).  The direction of benefit favored EVT for these sub-types of M2 segment 
MCA occlusion across most secondary outcomes. (Table 3) Benefit with EVT was seen in 
patients with anterior and posterior division M2 segment MCA occlusions, although smaller 
sample sizes meant results did not reach statistical significance (results not shown). No 
statistically significant heterogeneity in treatment effect however was noted across any M2 
segment MCA occlusion type.  
 
Discussion 
Endovascular therapy is now standard care in patients with ischemic stroke due to emergent 
anterior circulation large vessel occlusions.13 The Society of Neurointerventional Surgery (SNIS) 
recently revised its’ operational definition of Emergent large vessel occlusion Large Vessel 
Occlusion (ELVO) to include proximal M2 segment MCA occlusions in addition to intracranial 
carotid artery and M1 segment MCA occlusions.8 The American Stroke Guidelines assign this 
occlusion site a lesser degree of evidence of benefit with EVT when compared to the internal 
carotid artery or M1 segment MCA occlusions.14 This analysis of patients with M2 segment 
MCA occlusions from the HERMES Collaboration of 7 recent randomized controlled trials 
shows that EVT, especially in patients with proximal or dominant M2 segment MCA, results in 
improvement in functional ability at 90 days when compared to best medical care.  
 
Mechanical embolectomy devices are designed to suit the target arterial profile and access. 
Devices that work well in the proximal arterial segments are less likely to suit the arterial profile 
and access demands of distal arterial segments. A proximal segment or dominant M2 MCA 
branch however does not necessarily pose significantly increased difficulty in access when 
compared to the distal M1 segment MCA. This is substantiated by the fact that our analysis 
showed no intracerebral hemorrhage or major procedural complications in these patients. 
Moreover, patients with dominant M2 MCA branch occlusions have substantial volume of 
ischemic brain that could potentially be salvaged with EVT, thus increasing chances of benefit 
with this therapy. The successful reperfusion (mTICI 2b/3) rates noted in this analysis (59.2%) 
are significantly better than that obtained with intravenous alteplase in patients with M2 segment 
MCA occlusions.15 The reperfusion rates with EVT could improve further with the use of 
smaller diameter, next generation, stent retrievers and aspiration devices, further improving 
clinical outcomes in these patients.16 17 
 
Functional independence rates at 90 days noted in this study are comparable to results from a 
recent meta-analysis of 12 non-randomized studies reporting outcomes in patients with M2 
segment MCA occlusions treated with EVT (58.2% vs. 59% 90-day mRS 0-2 rates 
respectively).7 Interestingly, successful recanalization rates in these 12 non-randomized studies 
(81% overall) were higher than that noted in the current study (59.2%) while the symptomatic 
ICH (10% vs. 0%) and death (16% vs. 11.9%) rates were higher, highlighting the need for good 
patient selection and the use of appropriate endovascular techniques in these patients. 
 
Although this analysis represents high-quality randomized trial data, caution in interpretation is 
warranted. Differences in baseline characteristics (e.g. median baseline ASPECTS 9 in the EVT 
group vs. 8 in the control group, difference not statistically significant) may potentially explain 
better outcomes in the EVT group.  The seven recent RCTs testing EVT efficacy included in the 
HERMES Collaboration did not include all patients with M2 segment MCA occlusions (by 
design or otherwise).6 We cannot therefore rule out the possibility of selection bias influencing 
these results. Only 130 patients were available for analysis, potentially resulting in analysis of 
effect modification by M2 segment MCA occlusion type being underpowered to show efficacy 
of EVT. Nonetheless, point estimates of all reported clinical outcomes favouring EVT provides 
confidence that EVT benefits these patients. Finally, the choice of the primary outcome (mRS 0-
2 proportion at 90 days) was based on a careful assessment of the outcome distribution on the 
mRS scale and may therefore be considered post-hoc.12  
 
In conclusion, this analysis from recent randomized controlled trials provides additional 
evidentiary support for the efficacy of EVT vs. current non-endovascular acute stroke therapy in 
patients with M2 segment MCA occlusions.  
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Tables 
 
Table 1: Baseline characteristics and workflow processes in patients with M2 segment MCA occlusions in endovascular therapy 
(EVT) and control groups. 
 
Characteristic Endovascular Treatment Group 
Mean ± Standard Deviation (N=67) 
[Median] (Inter-quartile Range) 
Control Group 
Mean ± Standard Deviation 
(N=64*) 
[Median] (Inter-quartile Range) 
P value 
Age (years) 66.0 ± 13.7 (67) 
[66.4] (56.9,76.0) 
65.2 ± 12.0 (64) 
[65.9] (57.9,75.0) 
0.71 
Sex (Female, %) 53.7% (36/67) 46.9% (30/64) 0.49 
History of Hypertension (%) 61.2% (41/67) 59.4% (38/64) 0.86 
History of Dyslipidemia (%) 36.9% (24/65) 35.9% (23/64) 1.00 
History of Diabetes mellitus (%) 16.4% (11/67) 21.9% (14/64) 0.51 
Atrial fibrillation (%) 38.1% (24/63) 28.3% (17/60) 0.34 
NIHSS at baseline 14.4 ± 5.1 (67) 
[14.0] (11.0,19.0) 
15.4 ± 6.0 (63) 
[15.0] (11.0,20.0) 
0.32 
Baseline Non-contrast CT ASPECTS  8.6 ± 1.4 (67) 
[9.0] (8.0,10.0) 
8.1 ± 1.6 (64) 
[8.0] (7.0,10.0) 
0.06 
Intravenous alteplase administered  85.1% (57/67) 89.1% (57/64) 0.61 
Stroke onset to intravenous alteplase bolus 
(mins) 
119.6 ± 54.3 (56) [107.5] (83.8,136.3) 113.5 ± 44.8 (57) [100.0] 
(84.0,140.0) 
0.52 
Stroke onset to randomization (mins) 199.5 ± 84.1 (67) [180.0] 
(147.5,250.5) 
209.0 ± 76.5 (63) [193.0] 
(152.5,264.0) 
0.50 
Stroke onset to groin puncture (mins) 238.2 ± 90.3 (61) [220.0] (90.0,599.0) - - 
NIHSS, National Institute of Health Stroke Score; ASPECTS, Alberta Stroke Program Early CT Score 
*one patient with missing 90-day outcome was excluded from outcome analysis 
 
 
 
 
 
Table 2: Unadjusted and adjusted clinical and safety outcomes in patients with M2 segment 
MCA occlusions. 
 
   Unadjusted Adjusted 
Outcome 
Endovascular 
Treatment 
Group % 
(n/N) 
Control 
Group 
 % (n/N) 
Odds 
Ratio 
(95% CI) 
p-
value 
Odds Ratio 
(95% CI) 
p-
value 
mRS 0-2 58.2% (39/67) 39.7% (25/63) 
2.13 (1.05-
4.35) 0.04 
2.39 (1.08-
5.28) 0.03 
mRS at 90 days N/A N/A 1.88 (1.01-3.49) 0.05 
1.77 (0.94-
3.36) 0.08 
mRS 0-1 37.3% (25/67) 20.6% (13/63) 
2.62 (0.92-
7.45) 0.07 
2.71 (0.83-
8.83) 0.10 
NIHSS 0-2 at 
24h 26.9% (18/67) 
8.2% 
(5/61) 
4.11 (1.42-
11.9) 0.01 
3.82 (1.22-
11.95) 0.02 
sICH 0.0% (0/67) 7.9% (5/63) 0 0.03 -- -- 
Death 11.9% (8/67) 9.5% (6/63) 
1.29 (0.42-
3.95) 0.66 
1.33 (0.38-
4.7) 0.66 
 
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; sICH, 
symptomatic intracerebral hemorrhage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Unadjusted and adjusted clinical and safety outcomes in patients with proximal M2 
segment MCA occlusion, single vessel M2 segment middle cerebral artery (MCA) occlusions 
and dominant M2 segment MCA occlusions. 
 
      Unadjusted Adjusted 
Outcome 
Endovascular 
Treatment 
Group % 
(n/N) 
Control 
Group % 
(n/N) 
Odds Ratio 
(95% CI) p-value 
Odds Ratio 
(95% p-value 
Proximal M2 segment MCA (n=116) 
mRS 0-2 57.1% (36/63) 37.7% (20/53) 
2.24 (1.04-
4.81) 0.04 
2.68 (1.3-
6.37) 0.027 
mRS at 90 
days  N/A N/A 
1.96 (1.01-
3.8) 0.048 
1.95 (0.98-
3.87) 0.059 
mRS 0-1 36.5% (23/63) 18.9% (10/53) 
3.07 (0.95-
9.9) 0.063 
3.03 (0.81-
11.24) 0.101 
NIHSS 0-2 28.6% (18/63) 5.9% (3/51) 6.4 (1.77-23.21) 0.005 
6.09 (1.55-
23.99) 0.011 
sICH 0.0% (0/63) 7.5% (4/53) 0 0.041 -- -- 
Death 11.1% (7/63) 7.5% (4/53) 1.53 (0.42-5.55) 0.518 
1.58 (0.38-
6.63) 0.532 
Dominant M2 segment MCA (n=73) 
mRS 0-2 61.5% (24/39) 44.1% (15/34) 
1.91 (0.72-
5.1) 0.198 
4.08 (1.08-
15.48) 0.042 
mRS at 90 
days  N/A N/A 
1.96 (0.84-
4.6) 0.125 
2.76 (1.07-
7.11) 0.039 
mRS 0-1 35.9% (14/39) 17.6% (6/34) 3.04 (0.6-15.31) 0.182 
3.69 (0.8-
16.91) 0.098 
NIHSS 0-2 33.3% (13/39) 3.0% (1/33) 16 (1.96-130.5) 0.016 
40.42 (3.3-
495.48) 0.005 
sICH 0.0% (0/39) 5.7% (2/35) 0 0.22 -- -- 
Death 5.1% (2/39) 5.9% (2/34) 0.86 (0.12-6.5) 0.8882 
0.22 (0.02-
2.35) 0.215 
Single vessel M2 segment MCA (n=123) 
mRS 0-2 58.5% (38/65) 37.9% (22/58) 
2.34 (1.12-
4.91) 0.025 
2.73 (1.19-
6.27) 0.019 
mRS at 90 
days  N/A N/A 
2.03 (1.07-
3.86) 0.033 
1.92 (0.99-
3.73) 0.054 
mRS 0-1 38.5% (25/65) 19.0% (11/58) 
3.2 (1.06-
9.71) 0.042 
3.24 (0.93-
11.29) 0.067 
NIHSS 0-2 27.7% (18/65) 7.1% (4/56) 4.98 (1.57-15.77) 0.007 
4.98 (1.43-
17.34) 0.01 
sICH 0.0% (0/65) 6.8% (4/59) 0 0.048 -- -- 
Death 10.8% (7/65) 6.9% (4/58) 1.62 (0.45-5.85) 0.464 
1.69 (0.4-
7.08) 0.477 
 
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; sICH, 
symptomatic intracerebral hemorrhage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 
 
Figure 1: Modified Rankin Scale (mRS; unadjusted) distribution at 90 days in patients with 
baseline CT or MR Angiography defined M2 segment middle cerebral artery (MCA) occlusions. 
Benefit with endovascular thrombectomy (EVT) is better seen on the left side of the mRS scale.  
 
 
 
 
